Available from: Dariush Mozaffarian 1, Monica Agarwal 2, Monica Aggarwal 3, Lydia Alexander 4, Caroline M Apovian 5, Shagun Bindlish 6, Jonathan Bonnet 7, W Scott Butsch 8, Sandra Christensen 9, Eugenia Gianos 10, Mahima Gulati 11, Alka Gupta 12 13, Debbie Horn 14, Ryan M Kane 15 16, Jasdeep Saluja 17, Deepa Sannidhi 18, Fatima Cody Stanford 19 20, Emily A Callahan 1
[DOI] [PubMed] [Google Scholar] 486.Kashiwabara Y., Ambe K., Nakagawa T., Watanabe H
The combination of reduced oral intake from appetite suppression and fluid losses from gastrointestinal symptoms creates a vulnerable period, especially during the first 812 weeks of therapy or following dose increases
Mol Metab ;2018
"Chuck is honest, inspiring, and deeply relatable he understands the power of GLP-1s, and needed a partner to help him stay on track with treatment," said Zach Reitano, co-founder and CEO of Ro